<?xml version='1.0' encoding='utf-8'?>
<document id="31190741"><sentence text="Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets."><entity charOffset="46-58" id="DDI-PubMed.31190741.s1.e0" text="atorvastatin" /><entity charOffset="63-72" id="DDI-PubMed.31190741.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s1.e0" e2="DDI-PubMed.31190741.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s1.e0" e2="DDI-PubMed.31190741.s1.e1" /></sentence><sentence text="Purpose: The aims of this study was to investigate the mutual pharmacokinetic interactions between steady-state atorvastatin and metformin and the effect of food on the fixed-dose combined (FDC) tablet of atorvastatin and metformin extended release (XR)"><entity charOffset="112-124" id="DDI-PubMed.31190741.s2.e0" text="atorvastatin" /><entity charOffset="129-138" id="DDI-PubMed.31190741.s2.e1" text="metformin" /><entity charOffset="205-217" id="DDI-PubMed.31190741.s2.e2" text="atorvastatin" /><entity charOffset="222-231" id="DDI-PubMed.31190741.s2.e3" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e0" e2="DDI-PubMed.31190741.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e0" e2="DDI-PubMed.31190741.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e0" e2="DDI-PubMed.31190741.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e0" e2="DDI-PubMed.31190741.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e1" e2="DDI-PubMed.31190741.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e1" e2="DDI-PubMed.31190741.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e1" e2="DDI-PubMed.31190741.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e2" e2="DDI-PubMed.31190741.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31190741.s2.e2" e2="DDI-PubMed.31190741.s2.e3" /></sentence><sentence text=" Subjects and methods: Study 1, an open-labeled, fixed sequence, multiple-dose pharmacokinetic drug-drug interaction study, was divided into 2 parts" /><sentence text=" Atorvastatin (40 mg) or metformin (1,000 mg) XR tablets were administered once daily via mono- or co-therapy for 7 days"><entity charOffset="1-13" id="DDI-PubMed.31190741.s4.e0" text="Atorvastatin" /><entity charOffset="25-34" id="DDI-PubMed.31190741.s4.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s4.e0" e2="DDI-PubMed.31190741.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s4.e0" e2="DDI-PubMed.31190741.s4.e1" /></sentence><sentence text=" Plasma levels of atorvastatin and 2-OH-atorvastatin, were quantitatively determined for 36 h in part A (n=50) while metformin plasma concentration was measured up to 24 h in part B (n=16) after the last dosing"><entity charOffset="18-30" id="DDI-PubMed.31190741.s5.e0" text="atorvastatin" /><entity charOffset="35-52" id="DDI-PubMed.31190741.s5.e1" text="2-OH-atorvastatin" /><entity charOffset="117-126" id="DDI-PubMed.31190741.s5.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s5.e0" e2="DDI-PubMed.31190741.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s5.e0" e2="DDI-PubMed.31190741.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31190741.s5.e0" e2="DDI-PubMed.31190741.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31190741.s5.e1" e2="DDI-PubMed.31190741.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31190741.s5.e1" e2="DDI-PubMed.31190741.s5.e2" /></sentence><sentence text=" Study 2, a randomized, open-labeled, single-dose, two-treatment, two-period, two-sequence crossover study, involved 27 healthy subjects to investigate the impact of food intake on the pharmacokinetics of a combined atorvastatin/metformin XR 20/500 mg (CJ-30056 20/500 mg) tablet"><entity charOffset="216-228" id="DDI-PubMed.31190741.s6.e0" text="atorvastatin" /><entity charOffset="229-238" id="DDI-PubMed.31190741.s6.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s6.e0" e2="DDI-PubMed.31190741.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s6.e0" e2="DDI-PubMed.31190741.s6.e1" /></sentence><sentence text=" Results: After multiple doses of mono- or co-therapy of atorvastatin (40 mg) and metformin (1,000 mg) XR, the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the peak plasma concentration at steady state (Cmax,ss) and area under the plasma concentration-time curve during the dosing interval at steady state (AUCτ,ss) were 1"><entity charOffset="57-69" id="DDI-PubMed.31190741.s7.e0" text="atorvastatin" /><entity charOffset="82-91" id="DDI-PubMed.31190741.s7.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s7.e0" e2="DDI-PubMed.31190741.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s7.e0" e2="DDI-PubMed.31190741.s7.e1" /></sentence><sentence text="07 (0" /><sentence text="94-1" /><sentence text="22) and 1" /><sentence text="05 (0" /><sentence text="99-1" /><sentence text="10) for atorvastatin, 1"><entity charOffset="8-20" id="DDI-PubMed.31190741.s13.e0" text="atorvastatin" /></sentence><sentence text="06 (0" /><sentence text="96-1" /><sentence text="16) and 1" /><sentence text="16 (1" /><sentence text="10-1" /><sentence text="21) for 2-OH-atorvastatin, and 1"><entity charOffset="8-25" id="DDI-PubMed.31190741.s19.e0" text="2-OH-atorvastatin" /></sentence><sentence text="00 (0" /><sentence text="86-1" /><sentence text="18) and 0" /><sentence text="99 (0" /><sentence text="87-1" /><sentence text="13) for metformin, respectively"><entity charOffset="8-17" id="DDI-PubMed.31190741.s25.e0" text="metformin" /></sentence><sentence text=" Food delayed time to reach maximum concentration (tmax), decreased atorvastatin Cmax by 32% with a GMR (90% CI) of 0"><entity charOffset="68-80" id="DDI-PubMed.31190741.s26.e0" text="atorvastatin" /></sentence><sentence text="68 (0" /><sentence text="59-0" /><sentence text="78), and increased metformin AUCt by 56% with a GMR (90% CI) of 1" /><sentence text="56 (1" /><sentence text="43-1" /><sentence text="69)" /><sentence text=" Conclusion: No clinically relevant pharmacokinetic interaction was seen when atorvastatin was co-administered with metformin"><entity charOffset="78-90" id="DDI-PubMed.31190741.s33.e0" text="atorvastatin" /><entity charOffset="116-125" id="DDI-PubMed.31190741.s33.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s33.e0" e2="DDI-PubMed.31190741.s33.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s33.e0" e2="DDI-PubMed.31190741.s33.e1" /></sentence><sentence text=" Food appeared to change the absorption of atorvastatin and metformin from an FDC formulation"><entity charOffset="43-55" id="DDI-PubMed.31190741.s34.e0" text="atorvastatin" /><entity charOffset="60-69" id="DDI-PubMed.31190741.s34.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.31190741.s34.e0" e2="DDI-PubMed.31190741.s34.e0" /><pair ddi="false" e1="DDI-PubMed.31190741.s34.e0" e2="DDI-PubMed.31190741.s34.e1" /></sentence><sentence text=" These alterations were in accordance with those described with the single reference drugs when ingested with food" /><sentence text="" /></document>